Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Thomas George, Andrew Staron, Eric Burks, Raphael Szalat, Vaishali Sanchorawala

Blood (2025) 146 (Supplement 1): 5739.

https://doi.org/10.1182/blood-2025-5739

Published: 2025

Journal Articles

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Jackson Smith, Mehmet Samur, Srikanth Talluri, Domenico Maisano, Michela Cumerlato, Charlotte Royer, Fatima Zohura, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Nikhil Munshi, Raphael Szalat

Blood (2025) 146 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2025-3923

Published: 2025

Journal Articles

Effect of duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

Grace Ferri, Corina Beiner Martinez, Jose Acevedo, Sita Bhatt, Karina Verma, Maya Abdallah, Raphael Szalat, John Mark Sloan

Blood (2025) 146 (Supplement 1): 6170.

https://doi.org/10.1182/blood-2025-6170

Published: 2025

Journal Articles

Single-cell profiling in multiple myeloma: insights, problems, and promises

Mehmet Kemal Samur, Raphael Szalat, Nikhil C. Munshi

Blood (2023) 142 (4): 313–324.

https://doi.org/10.1182/blood.2022017145

Published: 2023

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, Anil Aktas Samur, Zachary Hunter, Masood Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth C. Anderson, Giovanni Parmigiani, Steven P. Treon, Mohamad Mohty, Nikhil C. Munshi, Mehmet Kemal Samur

Blood (2021) 138 (20): 1980–1985.

https://doi.org/10.1182/blood.2021011452

Published: 2021

Includes: Supplemental data

Journal Articles

Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Yao Yao, Tommaso Perini, Mehmet K. Samur, Raphael Szalat, Moritz Binder, Kenneth C. Anderson, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2021-152526

Published: 2021

Journal Articles

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Parth Shah, Anil Aktas-Samur, Mariateresa Fulciniti, Raphael Szalat, Masood A. Shammas, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi, Mehmet K. Samur

Blood (2021) 138 (Supplement 1): 461.

https://doi.org/10.1182/blood-2021-151647

Published: 2021

Journal Articles

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, Mariateresa Fulciniti, Sanika Derebail, Raphael Szalat, Giovanni Parmigiani, Jill Corre, Herve Avet-Loiseau, Mehmet K. Samur, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 545.

https://doi.org/10.1182/blood-2021-152317

Published: 2021

Journal Articles

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Raphael Szalat, Joshua Gustine, John Mark Sloan, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 2734.

https://doi.org/10.1182/blood-2021-144980

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139066

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

https://doi.org/10.1182/blood-2019-124980

Published: 2019

Journal Articles

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Blood (2019) 134 (Supplement_1): 1784.

https://doi.org/10.1182/blood-2019-131257

Published: 2019

Journal Articles

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Tommaso Perini, MD, Raphael Szalat, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Matthew Lawlor, Christopher J. Ott, PhD, Na Li, MD, Yan Xu, MD, Kenneth Wen, BS, Nicola Amodio, PhD, Eugenio Morelli, MD, Kenneth Anderson, MD, Fabio Ciceri, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 60.

https://doi.org/10.1182/blood-2018-99-118401

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Effect of duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

Single-cell profiling in multiple myeloma: insights, problems, and promises

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only